NEW YORK – BMO Financial Group on Friday said it has given $2 million to the McGill University Health Center Foundation to advance the precision oncology program at the Montreal-based university.
"Precision oncology is the future of cancer care," Rhian Touyz, executive director and CSO at MUHC's research institute, said in a statement. "It decreases use of one-size-fits-all treatments in favor of a personalized approach to each patient's disease."
The funds will support the creation of a suite of technologies and resources to support precision oncology efforts, including the development of organoids that can identify optimal treatments for patients and avoid drugs that they're unlikely to respond to.
BMO's donation is in response to the MUHC Foundation's $20 million "End Cancer" and the broader $200 million Dream Big campaigns.
"At BMO, we believe that the strongest progress can be made through collaborative and innovative approaches to solving complex problems," BMO CEO Darryl White said in a statement. "We're proud to help grow the good in Montreal — and beyond — with this investment in the MUHC's precision oncology program that will pioneer new cancer treatments, leading to transformational change in healthcare for all Canadians."